Sanofi to acquire Provention Bio for $2.9B

Sanofi, a French healthcare and pharmaceutical company, is acquiring American biopharmaceutical Provention Bio in a deal valued at $2.9 billion.

Provention Bio is focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), and its TZIELD (teplizumab-mzwv) therapy was approved in the United States last year. The therapy is the first and only therapy to delay the onset of Stage 3 T1D n adults and pediatric patients aged 8 years and older with Stage 2 T1D. 

According to Sanofi, the deal is a strategic fit for the company, and TZIELD adds an innovative, fully owned, first-in-class therapy to its core asset portfolio in general medicine. Plus, the therapy adds to Sanofi’s strategic shift toward products with a differentiated profile.

“The acquisition of Provention Bio builds on Sanofi’s mission to deliver best- and first-in-class medicines and resonates with our purpose of chasing the miracles of science for the benefit of people,” Olivier Charmeil, executive vice president of general medicines at Sanofi, said in a statement. “By coupling Provention Bio’s transformative innovation with Sanofi’s expertise, we aim to bring life-changing benefits to people at risk of developing Stage 3 type 1 diabetes. Any additional indications, approvals and pipeline assets only serve to further our excitement. Given our existing partnership and complementary work in the diabetes and immunology spaces, we foresee a seamless integration and execution.”

TZIELD is seen as having the potential as a transformative therapy in the U.S. and globally, potentially delaying the onset of Stage 3 T1D for some of the 65,000 people diagnosed every year. Stage 3 T1D has high health risks, including diabetic ketoacidosis, which can be life threatening. Patients who progress to Stage 3 T1D eventually require insulin injections for life. The therapy is currently approved in adults and pediatric patients aged 8 years and older with Stage 2 T1D.

Sanofi will maximize TZIELD’s potential through its capabilities. The two companies already have a co-promotion agreement that is delivering TZIELD to patients in need of this immune-mediated therapy.

TZIELD is also in late-stage clinical development for the treatment of pediatric and adolescent patients that are newly diagnosed with clinical T1D (Stage 3). The phase 3 trial, dubbed PROTECT, is underway, with top-line results expected in the second half of 2023. According to Sanofi, there are additional opportunities for TZIELD, including re-dosing and formulations as well as new therapeutic indications.

Under terms of the deal, Sanofi will acquire Provention Bio for $25 per share in case, for a total equity value of approximately $2.9 billion. Sanofi currently expects to complete the acquisition in the second quarter of 2023.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The scheme took place over a period of at least seven years, resulting in Medicare being billed for more than $70 million in fraudulent claims for unnecessary scans. 

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals.